# A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

> **NCT06572384** · PHASE3 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 440 (estimated)

## Conditions studied

- Lung Diseases, Interstitial

## Interventions

- **BIOLOGICAL:** Belimumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06572384
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-11
- **Primary completion:** 2028-10-18
- **Final completion:** 2028-12-13
- **Target enrollment:** 440 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06572384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06572384, "A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06572384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*